Discovery of Novel [1,2,4]Triazolo[1,5- a ]pyrimidine Derivatives as Novel Potent S-Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01283 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Kaizhao Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Laboratory Animal Center, State Key Laboratory of Esophageal Cancer…. Hauptthemen laut MEDLINE: S-Phase Kinase-Associated Proteins, Pyrimidines, Antineoplastic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Skp1-CUL1-ROC1-F-box E3 ubiquitin ligases' main component S-phase kinase-associated protein 2 (Skp2) is responsible for specifically recognizing ubiquitination-modified substrates to be degraded such as p27 and p21 in the case of binding with adaptor protein Cks1. Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-a]pyrimidine-based small molecules targeting Skp2. Among them, E35 demonstrated excellent inhibitory activities against the binding of Skp2-Cks1. In addition, compound E35 significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. Mechanistically, compound E35 markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. Furthermore, compound E35 showed an obvious inhibitory effect on MGC-803 xenograft mice without obvious toxicity. All of these results suggest that compound E35 might be a valuable lead compound for antitumor agents targeting Skp2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Laboratory Animal Center, State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan Provin…
- Key Laboratory of Technology of Drug Preparation (Zhengzhou University), Ministry of Education of China; Key Laboratory of Henan Province for Drug Quality and Evaluation; Institute of Pharmaceutical Sciences, Zhengzhou…
ORCID-Profile: Bing Zhao, Xiao-Jing Shi
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Hu, K., Luo, Y., Miao, P., Zhao, L., Zhao, B., Shi, X. J., & Liu, H. M. (2024). Discovery of Novel [1,2,4]Triazolo[1,5- a ]pyrimidine Derivatives as Novel Potent S-Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01283
Vancouver
Hu K, Luo Y, Miao P, Zhao L, Zhao B, Shi XJ, et al. Discovery of Novel [1,2,4]Triazolo[1,5- a ]pyrimidine Derivatives as Novel Potent S-Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01283
BibTeX
@article{Hu2024,
author = {Hu, Kaizhao and Luo, Yongqiang and Miao, Peipei and Zhao, Lidan and Zhao, Bing and Shi, Xiao-Jing and Liu, Hong-Min},
title = {Discovery of Novel [1,2,4]Triazolo[1,5- a ]pyrimidine Derivatives as Novel Potent S-Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01283}
}
EUVIMED